A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment
(the GFPC 0504 study)

[pdf]British journal of Cancer 2011_1-8[/pdf]